136 related articles for article (PubMed ID: 20811003)
1. Re: Impact of human papillomavirus (HPV)-6/11/16/18 vaccine on all HPV-associated genital diseases in young women.
Brewer NT; Reiter PL
J Natl Cancer Inst; 2010 Oct; 102(19):1517; author reply 1517-8. PubMed ID: 20811003
[No Abstract] [Full Text] [Related]
2. Impact of human papillomavirus (HPV)-6/11/16/18 vaccine on all HPV-associated genital diseases in young women.
Muñoz N; Kjaer SK; Sigurdsson K; Iversen OE; Hernandez-Avila M; Wheeler CM; Perez G; Brown DR; Koutsky LA; Tay EH; Garcia PJ; Ault KA; Garland SM; Leodolter S; Olsson SE; Tang GW; Ferris DG; Paavonen J; Steben M; Bosch FX; Dillner J; Huh WK; Joura EA; Kurman RJ; Majewski S; Myers ER; Villa LL; Taddeo FJ; Roberts C; Tadesse A; Bryan JT; Lupinacci LC; Giacoletti KE; Sings HL; James MK; Hesley TM; Barr E; Haupt RM
J Natl Cancer Inst; 2010 Mar; 102(5):325-39. PubMed ID: 20139221
[TBL] [Abstract][Full Text] [Related]
3. Primary and secondary prevention of cervical cancer--opportunities and challenges.
Markowitz LE; Unger ER; Saraiya M
J Natl Cancer Inst; 2009 Apr; 101(7):439-40. PubMed ID: 19318638
[No Abstract] [Full Text] [Related]
4. HPV 6, 11, 16, 18 vaccine in men. Inadequate assessment.
Prescrire Int; 2012 Sep; 21(130):208. PubMed ID: 23016251
[TBL] [Abstract][Full Text] [Related]
5. Quadrivalent papillomavirus vaccine in women over age 26. Cervical screening must remain a priority.
Prescrire Int; 2011 May; 20(116):121. PubMed ID: 21648175
[No Abstract] [Full Text] [Related]
6. Human papillomavirus quadrivalent vaccine: a look behind the numbers.
Flaherty DK; Alkhateeb FM
Ann Pharmacother; 2009 Apr; 43(4):740-4. PubMed ID: 19276314
[TBL] [Abstract][Full Text] [Related]
7. [Prophylactic vaccination against human papillomavirus].
Derancourt C
Ann Dermatol Venereol; 2007 Nov; 134(11):882-5; quiz 881, 886. PubMed ID: 18033077
[No Abstract] [Full Text] [Related]
8. No evidence for cross-protection of the HPV-16/18 vaccine against HPV-6/11 positivity in female STI clinic visitors.
Woestenberg PJ; King AJ; van der Sande MA; Donken R; Leussink S; van der Klis FR; Hoebe CJ; Bogaards JA; van Benthem BH; ;
J Infect; 2017 Apr; 74(4):393-400. PubMed ID: 28126492
[TBL] [Abstract][Full Text] [Related]
9. HPV antibody levels and clinical efficacy following administration of a prophylactic quadrivalent HPV vaccine.
Joura EA; Kjaer SK; Wheeler CM; Sigurdsson K; Iversen OE; Hernandez-Avila M; Perez G; Brown DR; Koutsky LA; Tay EH; García P; Ault KA; Garland SM; Leodolter S; Olsson SE; Tang GW; Ferris DG; Paavonen J; Lehtinen M; Steben M; Bosch X; Dillner J; Kurman RJ; Majewski S; Muñoz N; Myers ER; Villa LL; Taddeo FJ; Roberts C; Tadesse A; Bryan J; Lupinacci LC; Giacoletti KE; Lu S; Vuocolo S; Hesley TM; Haupt RM; Barr E
Vaccine; 2008 Dec; 26(52):6844-51. PubMed ID: 18930097
[TBL] [Abstract][Full Text] [Related]
10. Human papillomavirus quadrivalent (types 6, 11, 16, 18) recombinant vaccine (Gardasil).
Siddiqui MA; Perry CM
Drugs; 2006; 66(9):1263-71; discussion 1272-3. PubMed ID: 16827602
[TBL] [Abstract][Full Text] [Related]
11. Human papillomavirus vaccine for genotypes 6, 11, 16 and 18: new drug. Cervical cancer prevention: high hopes...
Prescrire Int; 2007 Jun; 16(89):91-4. PubMed ID: 17582921
[TBL] [Abstract][Full Text] [Related]
12. [The first vaccine against cancer: the human papillomavirus vaccine].
Bősze P
Orv Hetil; 2013 Apr; 154(16):603-18. PubMed ID: 23587540
[TBL] [Abstract][Full Text] [Related]
13. Quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine (Gardasil®): a review of its use in the prevention of premalignant genital lesions, genital cancer and genital warts in women.
McCormack PL; Joura EA
Drugs; 2010 Dec; 70(18):2449-74. PubMed ID: 21142263
[TBL] [Abstract][Full Text] [Related]
14. Health economic analysis of human papillomavirus vaccines in women of Chile: perspective of the health care payer using a Markov model.
Gomez JA; Lepetic A; Demarteau N
BMC Public Health; 2014 Nov; 14():1222. PubMed ID: 25424716
[TBL] [Abstract][Full Text] [Related]
15. [Cervix carcinoma--Austrian Vaccination Committee recommends HPV vaccination].
Six L; Joura EA
Wien Med Wochenschr; 2007; 157(5-6):130-2. PubMed ID: 17427010
[No Abstract] [Full Text] [Related]
16. [Diseases caused by human papillomavirus -- the possibilities and the public health advantages of prevention].
Acs N; Bata Z; Danko D; Hernádi Z; Kálmán M; Kornya L; Kovács J; Mézáros G; Molnár MP; Mór Z; Novák Z; Sobel G; Szentirmay Z; Takács L; Tisza T
Orv Hetil; 2012 Dec; 153 Suppl():3-38. PubMed ID: 23687666
[No Abstract] [Full Text] [Related]
17. Multistep carcinogenesis and genital papillomavirus infection. Implications for diagnosis and vaccines.
Rangel LM; Ramírez M; Torroella M; Pedroza A; Ibarra V; Gariglio P
Arch Med Res; 1994; 25(2):265-72. PubMed ID: 7919824
[TBL] [Abstract][Full Text] [Related]
18. [Vaccination against HPV in adults].
Gil Á
Rev Esp Quimioter; 2009 Nov; 22 Suppl 1():22-5. PubMed ID: 20084345
[No Abstract] [Full Text] [Related]
19. Gardasil: Introducing the new human papillomavirus vaccine.
McLemore MR
Clin J Oncol Nurs; 2006 Oct; 10(5):559-60. PubMed ID: 17063609
[TBL] [Abstract][Full Text] [Related]
20. Prophylactic human papillomavirus vaccines: past, present and future.
Anderson LA
Pathology; 2012 Jan; 44(1):1-6. PubMed ID: 22157686
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
